Literature DB >> 16849005

Evaluation of antimetastatic activity and systemic toxicity of camptothecin-loaded microspheres in mice injected with B16-F10 melanoma cells.

Cristiana Lima Dora1, Marcio Alvarez-Silva, Andréa Gonçalves Trentin, Tatiany Jovita de Faria, Daniel Fernandes, Robson da Costa, Marco Stimamiglio, Elenara Lemos-Senna.   

Abstract

PURPOSE: The aim of this work was to evaluate the pulmonary antimetastatic activity and the systemic toxicity of camptothecin-loaded microspheres.
METHODS: PCL microspheres containing camptothecin (CPT) were prepared by the emulsion solvent/evaporation method and characterized according to their encapsulation efficiency, particle size, morphology, and drug release. The ability of CPT to inhibit the lung metastasis was verified using an experimental mouse model intravenously injected with metastatic B16- F10 melanoma cells. The microspheres and the free drug were given intraperitoneally at a dose of 7 mg/kg at intervals of three or five days for 24 days. The systemic toxicity of CPT was evaluated by weight measurements, survival and hemograms of the animals.
RESULTS: The encapsulation efficiency was nearly 80%. The drug release was complete after 72 hours, but the burst effect increased from 7% to 35% with the increase in CPT content in the particles. It was observed during the in vivo essays that all groups treated with CPT had a decrease of nearly 70% in the number of lung metastases. However, systemic toxicity was verified in animals that received the free drug.
CONCLUSION: Camptothecin-loaded microspheres demonstrated similar therapeutic efficacy when compared to those of the free drug, but the toxicity was significantly reduced.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849005

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  7 in total

1.  A critical evaluation of drug delivery from ligand modified nanoparticles: Confounding small molecule distribution and efficacy in the central nervous system.

Authors:  Rebecca L Cook; Kyle T Householder; Eugene P Chung; Alesia V Prakapenka; Danielle M DiPerna; Rachael W Sirianni
Journal:  J Control Release       Date:  2015-10-22       Impact factor: 9.776

2.  Layer-by-layer nanoencapsulation of camptothecin with improved activity.

Authors:  Gaurav Parekh; Pravin Pattekari; Chaitanya Joshi; Tatsiana Shutava; Mark DeCoster; Tatyana Levchenko; Vladimir Torchilin; Yuri Lvov
Journal:  Int J Pharm       Date:  2014-02-06       Impact factor: 5.875

3.  Promoting antitumor activities of hydroxycamptothecin by encapsulation into acid-labile nanoparticles using electrospraying.

Authors:  Xiaoming Luo; Guoqing Jia; Haixing Song; Chaoyu Liu; Guannan Wu; Xiaohong Li
Journal:  Pharm Res       Date:  2013-07-25       Impact factor: 4.200

4.  Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery.

Authors:  Jie Liu; Zhaozhong Jiang; Shengmin Zhang; W Mark Saltzman
Journal:  Biomaterials       Date:  2009-07-25       Impact factor: 12.479

5.  Is an alternative drug delivery system needed for docetaxel? The role of controlling epimerization in formulations and beyond.

Authors:  Arehalli S Manjappa; Peeyush N Goel; Makam P Vekataraju; Kesarla S Rajesh; Kinjal Makwana; Mukesh Ukawala; Yuvraj Nikam; Rajiv P Gude; Rayasa S Ramachandra Murthy
Journal:  Pharm Res       Date:  2013-06-12       Impact factor: 4.200

6.  Stealth Liposomes (PEGylated) Containing an Anticancer Drug Camptothecin: In Vitro Characterization and In Vivo Pharmacokinetic and Tissue Distribution Study.

Authors:  Durgaramani Sivadasan; Muhammad H Sultan; Osama Ali Madkhali; Shahd Hassan Alsabei; Asia Abdullah Alessa
Journal:  Molecules       Date:  2022-02-06       Impact factor: 4.411

7.  Suppressive effect of juzen-taiho-to on lung metastasis of b16 melanoma cells in vivo.

Authors:  Takako Matsuda; Katsuhiko Maekawa; Kazuhito Asano; Tadashi Hisamitsu
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-05       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.